Cargando…

Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis

BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Linyan, Wu, Xin, Ma, Xuelei, Guo, Linghong, Zhu, Chenjing, Li, Qingfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312988/
https://www.ncbi.nlm.nih.gov/pubmed/28178131
http://dx.doi.org/10.1097/MD.0000000000005913
_version_ 1782508290226257920
author Chen, Linyan
Wu, Xin
Ma, Xuelei
Guo, Linghong
Zhu, Chenjing
Li, Qingfang
author_facet Chen, Linyan
Wu, Xin
Ma, Xuelei
Guo, Linghong
Zhu, Chenjing
Li, Qingfang
author_sort Chen, Linyan
collection PubMed
description BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in patients with soft tissue sarcoma. METHODS: The search and selection of eligible articles was conducted on PubMed and EMBASE. We applied hazard ratio (HR) and odd ratio (OR) to measure the correlation between SUVmax, MTV, and TLG with PFS and OS. The SUVmax was analyzed through subgroup in terms of histological grade and HR of posttreatment SUVmax was also assessed. RESULTS: Eleven studies with 582 patients were included. The pooled HRs of pretreatment SUVmax were 2.40 (95% CI: 1.38–4.17) for OS and 2.20 (95% CI: 1.47–3.30) for PFS. The HRs in terms of OS were 3.20 (95% CI: 1.71–5.98) based on MTV and 5.20 (95% CI: 2.34–11.56) based on TLG. Meanwhile, the predict results of pretreatment SUVmax on OR remained significant and the HRs of posttreatment SUVmax were 2.25 (95% CI: 1.33–3.80) for OS and 2.87 (95% CI: 1.81–4.55) for PFS. CONCLUSIONS: The pretreatment SUVmax, MTV, and TLG of (18)F-FDG PET-CT showed significant prognostic value for OS and the PET-CT can be used in identifying high-risk patients about progression and survival. The analysis for posttreatment SUVmax suggested PET-CT as a promising equipment in monitoring therapy response.
format Online
Article
Text
id pubmed-5312988
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53129882017-02-21 Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis Chen, Linyan Wu, Xin Ma, Xuelei Guo, Linghong Zhu, Chenjing Li, Qingfang Medicine (Baltimore) 5700 BACKGROUND: Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from (18)F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in patients with soft tissue sarcoma. METHODS: The search and selection of eligible articles was conducted on PubMed and EMBASE. We applied hazard ratio (HR) and odd ratio (OR) to measure the correlation between SUVmax, MTV, and TLG with PFS and OS. The SUVmax was analyzed through subgroup in terms of histological grade and HR of posttreatment SUVmax was also assessed. RESULTS: Eleven studies with 582 patients were included. The pooled HRs of pretreatment SUVmax were 2.40 (95% CI: 1.38–4.17) for OS and 2.20 (95% CI: 1.47–3.30) for PFS. The HRs in terms of OS were 3.20 (95% CI: 1.71–5.98) based on MTV and 5.20 (95% CI: 2.34–11.56) based on TLG. Meanwhile, the predict results of pretreatment SUVmax on OR remained significant and the HRs of posttreatment SUVmax were 2.25 (95% CI: 1.33–3.80) for OS and 2.87 (95% CI: 1.81–4.55) for PFS. CONCLUSIONS: The pretreatment SUVmax, MTV, and TLG of (18)F-FDG PET-CT showed significant prognostic value for OS and the PET-CT can be used in identifying high-risk patients about progression and survival. The analysis for posttreatment SUVmax suggested PET-CT as a promising equipment in monitoring therapy response. Wolters Kluwer Health 2017-02-10 /pmc/articles/PMC5312988/ /pubmed/28178131 http://dx.doi.org/10.1097/MD.0000000000005913 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 5700
Chen, Linyan
Wu, Xin
Ma, Xuelei
Guo, Linghong
Zhu, Chenjing
Li, Qingfang
Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title_full Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title_fullStr Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title_full_unstemmed Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title_short Prognostic value of (18)F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis
title_sort prognostic value of (18)f-fdg pet-ct-based functional parameters in patients with soft tissue sarcoma: a meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312988/
https://www.ncbi.nlm.nih.gov/pubmed/28178131
http://dx.doi.org/10.1097/MD.0000000000005913
work_keys_str_mv AT chenlinyan prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis
AT wuxin prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis
AT maxuelei prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis
AT guolinghong prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis
AT zhuchenjing prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis
AT liqingfang prognosticvalueof18ffdgpetctbasedfunctionalparametersinpatientswithsofttissuesarcomaametaanalysis